FLT3-ITD 검사의 국내 현황 조사(2021)

Abstract

Background: FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) is a crucial prognostic factor in acute myeloid leukemia and a target mutation for FLT3 inhibitor. It is also used for monitoring minimal residual disease after treatment. In this study, we conducted an online survey to investigate the status of the FLT3-ITD test in Korea. Methods: The survey was conducted through emails to the laboratory directors at university hospitals and tertiary medical institutions. The questionnaires included four questions on the use and performance of FLT3-ITD test by each institution, one on verification of detection and quantification limits, three on internal/external quality control, three on reporting formats and one on the institutions’ opinions on the FLT3-ITD allelic ratio. Results: Replies were received from 24 institutions. As a result of this survey, it was established that most institutions use fragment analysis to confirm the presence of FLT3-ITD and its allelic ratio. Most institutions reported FLT3-ITD allelic ratios during diagnosis and follow-up. Most laboratories established self-verified detection limits, internal controls, and participated in various external quality control programs for FLT3-ITD test. Conclusions: Most survey participants agreed on the need for test performance verification and external quality control to increase the accuracy and reliability of FLT3-ITD allelic ratios. We substantiate that the results of this survey will serve as a basis for setting the standard for the FLT3-ITD test in Korea, ultimately having a positive impact on patient care.